NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS

Akamai ( AKAM) estimates, target raised at Credit Suisse. Shares of AKAM now seen reaching $22.50. Estimates also increased, to match the company's new guidance. Neutral rating.

Alterra Capital ( symbol) upgraded to buy at TheStreet Ratings.

American Capital ( AGNC) estimates cut at UBS through 2012. Higher prepayment assumptions and a mix shift to lower coupon securities. Maintain $29 price target and Buy rating.

Avery Dennison ( AVY) numbers lowered at Credit Suisse. AVY estimates were cut through 2012. Company reduced its guidance. Neutral rating and new $34 price target.

Bank of America ( BAC) downgraded at Morgan Stanley from Overweight to Equal-weight. $10 price target. Earnings will continue to be pressured from macro growth concerns. $10 price target.

Bemis ( BMS) estimates, target cut at Jefferies. BMS estimates were reduced through 2012. Volumes are likely to remain sluggish. Hold rating and new $29 price target.

Boeing ( BA) estimates adjusted at UBS. BA 2012 EPS estimates lowered mainly for higher pension expenses. Maintain $66 price target and Neutral rating.

Brinker ( EAT) downgraded at Sterne Agee from Neutral to Underperform. Valuation call, based on a $20 price target.

Brinker estimates, target increased at UBS. Shares of EAT now seen reaching $27. Estimates also increased as company suggests October SSS are solid. Buy rating.

CA ( CA) estimates, target cut at Credit Suisse. Shares of CA now seen reaching $22. New product sales are declining. Neutral rating.

CA downgraded at Evercore to Equal-weight. Valuation call, based on a $24 price target.

Charles Schwab ( SCHW) numbers reduced at Credit Suisse. Shares of SCHW now seen reaching $16. Estimates also cut, as the company faces macro headwinds. Outperform rating.

Cisco ( CSCO) upgraded at UBS from Neutral to Buy. $19.75 price target. US networking demand remains solid, street estimates reasonable.

Cognizant ( CTSH) estimates, target increased at Morgan Stanley. CTSH estimates were raised through 2013. Company has solid operating momentum. Equal-weight rating and new $78 price target.

ConocoPhillips ( COP) numbers raised at UBS. Shares of COP now seen reaching $68. Estimates also increased on better than expected 3Q results. Neutral rating.

Dr. Pepper Snapple ( DPS) downgraded at Morgan Stanley from Equal-weight to Underweight. $36 price target. Profit trends remain weak.

Dr. Pepper Snapple estimates lowered at UBS through 2012. COGS inflation, higher spending to weigh on profitability near term. Maintain $40 price target and Neutral rating.

FMC Technologies ( FTI) numbers lowered at Credit Suisse. FTI estimates were cut through 2012. Company is struggling to manage its growth. Neutral rating and new $45 price target.

Ford ( F) estimates, target reduced at Credit Suisse. Shares of F now seen reaching $14. Estimates also cut, as the company is seeing lower sales in Europe. Neutral rating.

Ford estimates cut at UBS through 2011. Reflects lower guided operating margins. Maintain $15 price target and Buy rating.

Hess ( HES) estimates, target cut at UBS. Shares of HES now seen reaching $79. Estimates also lowered on higher E&P costs. Maintain Buy rating.

Hologic ( HOLX) downgraded at Ticonderoga from Buy to Neutral. New product launch is moving slower than expected.

Hospira ( HSP) upgraded at BofA/Merrill from Neutral to Buy. Valuation call, based on a $48 price target.

Itron ( ITRI) estimates, target lowered at Jefferies. ITRI estimates were cut through 2012. Company is facing higher warranty costs. Buy rating and new $46 price target.

Itron downgraded to sell at TheStreet Ratings.

Jarden ( JAH)estimates, target upped at Oppenheimer. JAH estimates were boosted through 2012. Company is posting higher organic sales growth. Outperform rating and new $44 price target.

Mastercard ( MA) estimates, target raised at Morgan Stanley. Shares of MA now seen reaching $375. Estimates also increased, given better industry trends. Overweight rating.

MeadWestvaco ( MWV) downgraded at BMO from Outperform to Underperform. Industry prices are falling. $25 price target.

Norfolk Southern ( NSC) numbers raised at Credit Suisse. Shares of NSC now seen reaching $90. Estimates also increased, as the company is realizing higher margins. Outperform rating.

Novellus ( NVLS) estimates, target boosted at Credit Suisse. Shares of NVLS now seen reaching $40. Estimates also upped, to match the company's new guidance. Neutral rating.

O'Reilly Automotive ( ORLY) numbers boosted at Credit Suisse. Shares of ORLY now seen reaching $76. Estimates also upped, as the company continues to deliver solid growth. Outperform rating.

Owens Corning ( OC) upgraded at Stifel from Hold to Buy. Valuation call, based on a $36 price target.

Panera Bread ( PNRA) downgraded at Sterne Agee from Buy to Neutral. Valuation call, despite rising estimates.

Praxair ( PX) downgraded at BofA/Merrill from Buy to Underperform. Valuation call, based on a $110 price target.

Range Resources ( RRC) numbers upped at Credit Suisse. RRC estimates were boosted through 2013. Company boosted its production guidance. Outperform rating and new $81 price target.

Sealed Air ( SEE) numbers reduced at Jefferies. Shares of SEE now seen reaching $24. Estimates also cut, as the company has limited sales visibility. Buy rating.

Sprint Nextel ( S) estimates lowered at UBS through 2012. 2012 wireless margins will come down to 10.5% of sales. Maintain $2.75 price target and Neutral rating.

Thermo Fisher ( TMO) numbers cut at Oppenheimer. TMO estimates were reduced through 2012. Company is seeing lower end-market demand. Outperform rating and new $59 price target.

Thermo Fisher numbers cut at UBS. Shares of TMO now seen reaching $60. Estimates also lowered on weakness in academic spending. Buy rating.

Vale ( VALE) estimates, target cut at Morgan Stanley. VALE estimates were reduced through 2012. Company is leveraged to lower iron ore prices. Equal-weight rating and new $29 price target.

Visa ( V) downgraded at FBR to Market Perform from Outperform. $96 price target. Company is increasing incentives and domestic debit volumes are falling.

Wellpoint ( WLP) estimates, target increased at Oppenheimer. WLP estimates were raised through 2012. Company is realizing higher enrollment growth. Outperform rating.

WellPoint estimates raised at UBS through 2011. Management reiterated long term EPS growth target of 10%. Maintain $79price target and Buy rating.
This article was written by a staff member of TheStreet.